Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 2, 2013, Pages 225-232

  Viswanathan, Vijay ^a   Mohan, Viswanathan ^b   Subramani, Poongothai ^b   Parthasarathy, Nandakumar ^b   Subramaniyam, Gayathri ^b   Manoharan, Deepa ^b   Sundaramoorthy, Chandru ^a   Gnudi, Luigi ^c   Karalliedde, Janaka ^c   Viberti, Giancarlo ^c  

^a MV Hospital for Diabetes   (India)

^b MADRAS DIABETES RESEARCH FOUNDATION   (India)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMILORIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; FEMALE; FLUID RETENTION; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA VOLUME; RADIOIMMUNOASSAY;

ADULT; AGED; AMILORIDE; DIABETES MELLITUS, TYPE 2; DIURETICS; EDEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; SPIRONOLACTONE; THIAZOLIDINEDIONES;

EID: 84875028863     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06330612     Document Type: Article

References (27)

1. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 351:1106-1118, 2004
2. NestoRW, BellD, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256-263, 2004
3. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. NEngl J Med 356: 2457-2471
4. Rosen CJ: Revisiting the rosiglitazone story-lessons learned. N Engl J Med 363:803-8066, 2010
5. Karalliedde J, Viberti GC: Comment on: Boden et al. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: Prevention of fluid retention. Diabetes 56:e3; author reply e4, 2007
6. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nature Med 11:861-866, 2005
7. Guan Y, Zhang Y, Davis L, Breyer MD: Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 273(6 pt 2): F1013-1022, 1997
8. ZhangH, Zhang A, KohanDE, Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specific deletion of peroxisome proliferatoractivated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A102: 9406-9411, 2005
9. Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, DechenesG, Rossier B, CunardR, Stockand J: Thiazolidinedioneinduced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol 20: 721-729, 2009
10. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G: Effect of various diuretic treatments on rosiglitazoneinduced fluid retention. J AmSocNephrol 17: 3482-3490, 2006
11. Karalliedde J, Buckingham RE: Thiazolidinediones and their fluid-related adverse effects: Facts, fiction and putative management strategies. Drug Safety 30: 741-753, 2007
12. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1:S5-20, 2003
13. Dill DB, Costill DL: Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol 37:247-248, 1974
14. GlaxoSmithKline: Result summary for 49653/342 2006. Available at: http://www.gsk-clinicalstudyregister.com/result_detail.jsp? protocolId=49653%2f342&studyId=7F3C40C1-B73A-4FE0-8CB8-817A012261C6&compound=rosiglitazone. Accessed May 1, 2012
15. Brown MJ: The choice of diuretic in hypertension: Saving the baby from the bathwater. Heart 97:1547-1551, 2011
16. IndiaCIMS:Available at: http://mims.com/India/drug/info/amiloride/?q=amiloride&type=full. Accessed May 1, 2012
17. Man IO, Glover K, Nixon P, Poyton R, Terre R, Morrissey MC: Effect of body position on foot and ankle volume in healthy subjects. Clin Physiol Funct Imag 24: 323-326, 2004
18. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 28:1245-1249, 2005
19. Hsu JC, editor: Multiple Comparisons Theory and Methods, London, Chapman and Hall, 1997
20. Viswanathan V, ViswanathanM, Karalliedde J, Tilak P, Subramani P, Agarwal S, Parthasarathy N, Subramaniyan G, Manoharan D, Chandru C, Viberti GC: Incidence of fluid retention among South Asian type 2 diabetic patient initiated on rosiglitazone therapy [Abstract]. Diabetes 59: A564A, 2010
21. Warnock DG: Liddle syndrome: Genetics and mechanisms of Na+ channel defects. Am J Med Sci 322: 302-307, 2001
22. Goel K, Misra A, Vikram NK, Poddar P, Gupta N: Subcutaneous abdominal adipose tissue is associated with the metabolic syndrome in Asian Indians independent of intra-abdominal and total body fat. Heart 96: 579-583, 2010
23. Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, Defronzo RA, Gastaldelli A: Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus. Clin Pharmacol Therap 82: 275-281, 2007
24. Katz AM: Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. NEngl JMed 322: 100-110, 1990
25. Berlie HD, Kalus JS, Jaber LA: Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract 76: 279-289, 2007
26. Food and Drug Administration: FDA Drug Safety Communication: Updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. May 18, 2011 Available at: http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm. Accessed May 1, 2012
27. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 370:1129-1136, 2007